WuXi STA Closes Purchase of Swiss BMS plant
The Couvet facility opened in 2018 has a state-of-the-art tablet & capsule manufacturing and packaging capabilities. By enhancing its network, WuXi STA said it can “better support customers’ long-term needs globally, as they bring new and existing commercial manufacturing projects from their pipelines to a plant that has the capability and capacity to supply drug products to major global markets.”
With the transaction, the company has increased its global presence to eight R&D and manufacturing sites across Asia, North America and Europe, including the recently announced Middletown site in the US state of Delaware.
“Through combining resources of the Couvet site with our other facilities, we continue strengthening and broadening our capacity and capabilities to better support our global customers in delivering innovative medicines to patients in need,” said Minzhang Chen, co-CEO of WuXi AppTec.
Author: Dede Williams, Freelance Journalist
-
WuXi STA, CDMO arm of WuXi AppTec, has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland, from US pharma Bristol Myers Squibb. The Chinese company said the state-of-the-art facility significantly enhances its European capacity. (c) BMS
